UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases in the United States, Europe, and internationally.
Flawless balance sheet, good value and pays a dividend.
Share Price & News
How has UCB's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: UCB's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: UCB exceeded the Austrian Pharmaceuticals industry which returned 18.4% over the past year.
Return vs Market: UCB exceeded the Austrian Market which returned -18.2% over the past year.
Price Volatility Vs. Market
How volatile is UCB's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is UCB undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: UCB (€88.6) is trading below our estimate of fair value (€121.68)
Significantly Below Fair Value: UCB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: UCB is good value based on its PE Ratio (21x) compared to the Pharmaceuticals industry average (23.7x).
PE vs Market: UCB is poor value based on its PE Ratio (21x) compared to the Austrian market (10.8x).
Price to Earnings Growth Ratio
PEG Ratio: UCB is poor value based on its PEG Ratio (3.4x)
Price to Book Ratio
PB vs Industry: UCB is good value based on its PB Ratio (2.4x) compared to the XE Pharmaceuticals industry average (3.3x).
How is UCB forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: UCB's forecast earnings growth (6.1% per year) is above the savings rate (0.5%).
Earnings vs Market: UCB's earnings (6.1% per year) are forecast to grow slower than the Austrian market (22.3% per year).
High Growth Earnings: UCB's earnings are forecast to grow, but not significantly.
Revenue vs Market: UCB's revenue (1.8% per year) is forecast to grow slower than the Austrian market (3.6% per year).
High Growth Revenue: UCB's revenue (1.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: UCB's Return on Equity is forecast to be low in 3 years time (12.7%).
How has UCB performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: UCB has high quality earnings.
Growing Profit Margin: UCB's current net profit margins (16.1%) are lower than last year (17.1%).
Past Earnings Growth Analysis
Earnings Trend: UCB's earnings have grown significantly by 27.9% per year over the past 5 years.
Accelerating Growth: UCB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: UCB had negative earnings growth (-0.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (5.5%).
Return on Equity
High ROE: UCB's Return on Equity (11.6%) is considered low.
How is UCB's financial position?
Financial Position Analysis
Short Term Liabilities: UCB's short term assets (€3.3B) exceed its short term liabilities (€2.4B).
Long Term Liabilities: UCB's short term assets (€3.3B) exceed its long term liabilities (€1.7B).
Debt to Equity History and Analysis
Debt Level: UCB's debt to equity ratio (16.9%) is considered satisfactory.
Reducing Debt: UCB's debt to equity ratio has reduced from 43.1% to 16.9% over the past 5 years.
Debt Coverage: UCB's debt is well covered by operating cash flow (74.6%).
Interest Coverage: UCB's interest payments on its debt are well covered by EBIT (25.8x coverage).
What is UCB's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: UCB's dividend (1.4%) isn’t notable compared to the bottom 25% of dividend payers in the Austrian market (1.68%).
High Dividend: UCB's dividend (1.4%) is low compared to the top 25% of dividend payers in the Austrian market (4.96%).
Stability and Growth of Payments
Stable Dividend: UCB's dividends per share have been stable in the past 10 years.
Growing Dividend: UCB's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (29.4%), UCB's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: UCB's dividends in 3 years are forecast to be well covered by earnings (23.6% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jean-Christophe Tellier (60yo)
Mr. Jean-Christophe Tellier has been the Chief Executive Officer and Executive Director of UCB SA since January 1, 2015 and April 24, 2014 respectively and also serves as an Interim Chief Financial Officer ...
CEO Compensation Analysis
Compensation vs Market: Jean-Christophe's total compensation ($USD97.32K) is below average for companies of similar size in the Austrian market ($USD3.83M).
Compensation vs Earnings: Jean-Christophe's compensation has been consistent with company performance over the past year.
|CEO, Interim CFO & Executive Director||5.42yrs||€87.00k||no data|
|Executive VP & Chief Scientific Officer||2.67yrs||no data||no data|
|Executive VP & General Counsel||1.25yrs||no data||no data|
|Executive VP & Chief Human Resources Officer||0.33yr||no data||no data|
|Chief Medical Officer||12.25yrs||no data||no data|
|Executive VP of Immunology Solutions & Head of US||5.33yrs||no data||no data|
|Executive VP of Neurology Solutions & Head of EU/International||0.75yr||no data||no data|
|Chief Accounting Officer & CFO of Patient Value Functions||7.25yrs||no data||no data|
|Executive Vice President of Supply & Technology Solutions||0.75yr||no data||no data|
|Head of Investor Relations||10.42yrs||no data||no data|
Experienced Management: UCB's management team is considered experienced (4 years average tenure).
|CEO, Interim CFO & Executive Director||5.42yrs||€87.00k||no data|
|Honorary Chairman||no data||€70.00k||no data|
|Honorary Chairman||15.42yrs||€15.50k||no data|
|Honorary Deputy Chairman||no data||€28.50k||no data|
|Independent Director||10.17yrs||€120.50k||no data|
|Honorary Chairman||no data||€30.00k||no data|
|Honorary Chairman||no data||€49.00k||no data|
|Independent Vice Chairman||3.08yrs||€147.50k||no data|
Experienced Board: UCB's board of directors are considered experienced (4.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
UCB SA's company bio, employee growth, exchange listings and data sources
- Name: UCB SA
- Ticker: UCB
- Exchange: WBAG
- Founded: 1928
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €16.722b
- Shares outstanding: 188.53m
- Website: https://www.ucb.com
Number of Employees
- UCB SA
- AllEe de la Recherche, 60
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|UCBJ.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Jan 1980|
|UNC||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jan 1980|
|UCB||ENXTBR (Euronext Brussels)||Yes||Common Shares||BE||EUR||Jan 1980|
|0NZT||LSE (London Stock Exchange)||Yes||Common Shares||GB||EUR||Jan 1980|
|UCBB||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Shares||GB||EUR||Jan 1980|
|UCB||WBAG (Wiener Boerse AG)||Yes||Common Shares||AT||EUR||Jan 1980|
|UNC||ETLX (Eurotlx)||Yes||Common Shares||IT||EUR||Jan 1980|
|UCBJ.Y||OTCPK (Pink Sheets LLC)||UNSPONSORED ADR||US||USD||Feb 2009|
UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases in the United States, Europe, and internationally. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; and Nayzilam, a nasal spray rescue treatment for seizure clusters. It also provides Zyrtec and Xyzal for allergies; Nootropil for memory problems; and Xyrem for narcolepsy. In addition, the company offers Evenity for the treatment of osteoporosis; bimekizumab for treating psoriasis, psoriatic arthritis, and axial spondyloarthritis; and dapirolizumab pegol for systemic lupus erythematosus. Further, it is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; UCB7858 for immunology; and UCB0599 for neurology; and UCB0107 for progressive supranuclear palsy. Additionally, the company engages in contract manufacturing activities. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, and Otsuka. The company was founded in 1928 and is headquartered in Brussels, Belgium.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/03 10:22|
|End of Day Share Price||2020/06/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.